Association between adherence to warfarin and thrombotic events in patients with antiphospholipid syndrome in Japan: A claims-based retrospective cohort study

被引:1
作者
Byambajav, Tserenlkham [1 ,2 ]
Waki, Takashi [1 ]
Miura, Katsuyuki [1 ,3 ]
Tanaka-Mizuno, Sachiko [1 ,4 ]
机构
[1] Shiga Univ Med Sci, Dept Publ Hlth, Otsu, Shiga, Japan
[2] Mongolian Natl Univ Med Sci, Sch Pharm, Dept Clin Pharm & Pharmaceut Management, Ulaanbaatar, Mongolia
[3] Shiga Univ Med Sci, NCD Epidemiol Res Ctr NERC, Otsu, Shiga, Japan
[4] Kyoto Univ, Grad Sch Med & Publ Hlth, Dept Digital Hlth & Epidemiol, Kyoto, Japan
关键词
adherence; antiphospholipid syndrome; persistence; thrombosis; warfarin; INTERNATIONAL CONSENSUS STATEMENT; HIGH-RISK PATIENTS; VENOUS THROMBOEMBOLISM; ATRIAL-FIBRILLATION; CLASSIFICATION CRITERIA; ANTICOAGULATION; EPIDEMIOLOGY; PERSISTENCE; MANAGEMENT; RECURRENCE;
D O I
10.1002/pds.5343
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose We aimed to evaluate adherence and persistence to warfarin therapy among patients with antiphospholipid syndrome (APS) and investigate the association between adherence and thrombotic events in those patients. Methods We conducted a retrospective cohort study using the Japan Medical Data Center claims database from 2005 to 2018. Patients with APS receiving warfarin treatment were included in this study. Adherence and persistence were evaluated using the proportion of days covered (PDS) and refill gap methods, respectively. Demographic characteristics of patients were obtained. Kaplan-Meier curves with log-rank tests and Cox regression models were used to examine the association between adherence or persistence and time to thrombotic events. Results A total of 186 patients (mean age: 46.5 +/- 12.4 years, females 68.8%) were included in this study. No significant differences were observed in risk factors for thrombosis and cardiovascular diseases among groups. Most patients were adherent (91.4%) and persistent (88.2%) to warfarin treatment. Adherent and persistent patients had a significantly higher rate of thrombotic event-free survival than nonadherent and nonpersistent patients (p < 0.05). Multivariable Cox regression showed that the risk of thrombotic events was higher in nonadherent patients (with a hazard ratio of 3.23 [95% confidence interval CI: 1.15-9.11]) and in nonpersistent patients (with a hazard ratio of 3.45 [95% CI: 1.35-8.82]). Conclusions In patients with APS, nonadherence and nonpersistence to warfarin treatment was associated with a higher risk of thrombotic events, suggesting the careful monitoring of those patients.
引用
收藏
页码:149 / 157
页数:9
相关论文
共 51 条
[31]   Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban [J].
Lip, Gregory Y. H. ;
Pan, Xianying ;
Kamble, Shital ;
Kawabata, Hugh ;
Mardekian, Jack ;
Masseria, Cristina ;
Phatak, Hemant .
PLOS ONE, 2018, 13 (04)
[32]   Risk of recurrent venous thromboembolism after discontinuation of vitamin K antagonist treatment: a nested case-control study [J].
Martinez, C. ;
Katholing, A. ;
Folkerts, K. ;
Cohen, A. T. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 (07) :1374-1383
[33]   Small Data Challenges of Studying Rare Diseases [J].
Mitani, Aya A. ;
Haneuse, Sebastien .
JAMA NETWORK OPEN, 2020, 3 (03)
[34]   International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) [J].
Miyakis, S ;
Lockshin, MD ;
Atsumi, T ;
Branch, DW ;
Brey, RL ;
Cervera, R ;
Derksen, RHWM ;
De Groot, PG ;
Koike, T ;
Meroni, PL ;
Reber, G ;
Shoenfeld, Y ;
Tincani, A ;
Vlachoyiannopoulos, PG ;
Krilis, SA .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (02) :295-306
[35]   Medication taking behaviors in patients taking warfarin versus direct oral anticoagulants: A systematic review [J].
Mohan, Anjana ;
Wanat, Matthew A. ;
Abughosh, Susan M. .
EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2019, 17 (06) :427-434
[36]   Current management of venous thromboembolism in Japan: Current epidemiology and advances in anticoagulant therapy [J].
Nakamura, Mashio ;
Yamada, Norikazu ;
Ito, Masaaki .
JOURNAL OF CARDIOLOGY, 2015, 66 (5-6) :451-459
[37]   Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT) [J].
Palareti, G ;
Leali, N ;
Coccheri, S ;
Poggi, M ;
Manotti, C ;
DAngelo, A ;
Pengo, V ;
Erba, N ;
Moia, M ;
Ciavarella, N ;
Devote, G ;
Berrettini, M ;
Musolesi, S .
LANCET, 1996, 348 (9025) :423-428
[38]   Clinical course of high-risk patients diagnosed with antiphospholipid syndrome [J].
Pengo, V. ;
Ruffatti, A. ;
Legnani, C. ;
Gresele, P. ;
Barcellona, D. ;
Erba, N. ;
Testa, S. ;
Marongiu, F. ;
Bison, E. ;
Denas, G. ;
Banzato, A. ;
Jose, S. Padayattil ;
Iliceto, S. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (02) :237-242
[39]   Risk factors for venous and arterial thrombosis [J].
Previtali, Emanuele ;
Bucciarelli, Paolo ;
Passamonti, Serena M. ;
Martinelli, Ida .
BLOOD TRANSFUSION, 2011, 9 (02) :120-138
[40]   Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction [J].
Rasmussen, Jeppe N. ;
Chong, Alice ;
Alter, David A. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (02) :177-186